Effect of Daily Oral Administration of Salmon Milt Peptides on Postprandial Blood Glucose Level: Placebo-controlled Double Blind Cross Over Clinical Trial

Effect of Daily Oral Administration of Salmon Milt Peptides on Postprandial Blood Glucose Level: Placebo-controlled Double Blind Cross Over Clinical Trial - Effect of Daily Oral Administration of Salmon Milt Peptides on Postprandial Blood Glucose Level

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000024976

Enrollment

Registered

2016-11-24

Start date

2016-12-16

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy adults

Interventions

Daily intake for 2 weeks salmon milt peptides tablets, and take wash out period for 2 weeks, and then, daily intake for 2 weeks placebo tablets. Daily intake for 2 weeks placebo tablets, and take wash

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Subjects with high serum glucose levels at 60 min after oral glucose load. 2. Subjects whose HOMA-IR is <1.6. 3. Subjects who agree to participate in the current study with written informed consent.

Exclusion criteria

Exclusion criteria: 1.Subjects who are under treatment and medication for diabetes and dyslipidemia. 2.Subjects whose HbA1c>=6.5% 3.Subjects whose FBG>=126 mg/dl. 4.Subjects whose BFP>=40% 5.Subjects with serious disease and infection. 6.Subjects with clinical history of gastrointestinal surgery. 7.Subjects with unusually high and/or low blood pressure, or with abnormal hematological data. 8.Subjects with serious anemia. 9.Subjects with frequent complaints of post-menopausal symptoms. 10.Subjects with a history of allergy to medicine and food, especially salmon. 11.Subjects regularly take medicine, functional foods and/or supplements which would affect glucose metabolism. 12.Subjects regularly take medicine, functional foods and/or supplements which would affect lipid metabolism. 13.Subjects who are heavy smokers and alcohol addicts, or subjects with irregular lifestyle. 14.Subjects who donated either 400 ml whole blood within 12 weeks (men) /16 weeks (women) or 200 ml whole blood within 4 weeks or blood components within 2 weeks prior to this study. 15.Subjects who are pregnant or under lactation, or ones who would be expected to be pregnant during the study. 16.Subjects who participate in other clinical trials within the last 4 weeks prior to the current clinical trial. 17.Subjects who are not eligible due to physician's judgment.

Design outcomes

Primary

Measure	Time frame
FBG at baseline and at 30 min, 60 min, 90 min, 120 min after oral glucose load, and AUC.	—

Secondary

Measure	Time frame
Fasting Insulin level at baseline and at 30 min, 60 min, 90 min, 120 min after oral glucose load, and AUC.	—

Countries

Japan

Contacts

Public ContactDir. Prof. Jun NISHIHIRA, M.D., Ph.D.

Hokkaido Information University Health Information Science Center

nishihira@do-johodai.ac.jp011-385-4430

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026